Cargando…

Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease

PURPOSE: The first-line antithyroid drug for children and adolescents with Graves’ disease (GD) is methimazole (MMI). This study evaluated the relationship between the initial MMI dose and the clinical course of GD after treatment. METHODS: We studied the efficacy of the initial MMI dose and the rel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyun Gyung, Yang, Eun Mi, Kim, Chan Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Pediatric Endocrinology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505040/ https://www.ncbi.nlm.nih.gov/pubmed/34610704 http://dx.doi.org/10.6065/apem.2142046.023

Ejemplares similares

Adverse Events Associated with Methimazole Therapy of Graves' Disease in Children
por: Rivkees, Scott A., et al.
Publicado: (2010)

Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report
por: Azizi, Fereidoun, et al.
Publicado: (2021)

Different doses of methimazole treatment of children and adolescents with graves’ disease: a clinical study based on 161 cases of outpatients
por: Li, Peng, et al.
Publicado: (2023)

Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease
por: Roh, Eun, et al.
Publicado: (2013)

Impact of Methimazole Treatment on Magnesium Concentration and Lymphocytes Activation in Adolescents with Graves’ Disease
por: Klatka, Maria, et al.
Publicado: (2013)

Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
por: Matsushita, Rie, et al.
Publicado: (2010)

Methimazole-Induced Pleural Effusion in the Setting of Graves' Disease
por: Khine, Le Yu, et al.
Publicado: (2019)

Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013
por: Hwang, Sun Mi, et al.
Publicado: (2016)

Long-term methimazole therapy in Graves’ hyperthyroidism and adverse reactions: a Danish multicenter study
por: Karmisholt, J, et al.
Publicado: (2022)

Polyarthritis Caused by Methimazole in Two Japanese Patients with Graves’ Disease
por: Nihei, Hiroko, et al.
Publicado: (2013)

Profound Hypothyroidism 21 Days After Methimazole Initiation in a Patient With Graves’s Disease and Liver Cirrhosis
por: Hammami, Safa, et al.
Publicado: (2021)

SAT-625 Dose-Dependent, Methimazole-Induced Agranulocytosis in a Pregnant Hispanic Woman with Grave's Disease
por: Bello, Fatimah, et al.
Publicado: (2019)

SUN-517 Methimazole-Induced Neutropenia in Premature Twins with Graves’ Disease
por: Ballestas, Estefania Rodriguez, et al.
Publicado: (2020)

A Rare Case of Anaphylaxis to Methimazole in a Patient With Graves’ Disease
por: Garg, Dave, et al.
Publicado: (2021)

Methimazole Desensitization in a 4-Year-Old With Refractory Graves Disease
por: Schneider Aguirre, Rebecca, et al.
Publicado: (2021)

FRI505 A Rare Case Of Methimazole Induced Grave Agranulocytosis
por: Barua, Nabonita, et al.
Publicado: (2023)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Chylous Ascites: A Rare Adverse Effect of Methimazole Treatment for Grave's Disease—A Case Report and Review of the Literature
por: Khoury, Tawfik, et al.
Publicado: (2015)

Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

Clinical Trial of Four Weeks of Combination Therapy with Low-dose Methimazole and a Cholesterol Absorption Inhibitor as the Initial Treatment for Childhood-onset Graves’ Disease
por: Takakuwa, Satoshi, et al.
Publicado: (2014)

Insulin autoimmune syndrome induced by methimazole in a Korean girl with Graves' disease
por: Lee, Sun Hee, et al.
Publicado: (2013)

Efficacy of methimazole before the administration of radioactive iodine in the management of Graves’ disease: a systematic review and meta-analysis
por: Bolakale-Rufai, Ikeoluwapo Kendra, et al.
Publicado: (2023)

Erratum to: Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease
Publicado: (2021)

Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease
por: Puthenpura, Vidya, et al.
Publicado: (2016)

Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated Pediatric Graves’ Disease Patients
por: Starosz, Aleksandra, et al.
Publicado: (2021)

Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial
por: Azizi, Fereidoun, et al.
Publicado: (2021)

Methimazole-Induced Aplastic Anemia with Concomitant Hepatitis in a Young Filipina with Graves’ Disease
por: Wijaya, Natalia, et al.
Publicado: (2019)

THU669 Time To Achieve Euthyroidism In Graves Disease Using Methimazole In An Urban Population
por: Sultana Habbsa, Samima, et al.
Publicado: (2023)

A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole
por: Miyashita, Kazuyuki, et al.
Publicado: (2013)

Very rare case of Graves’ disease with resistance to methimazole: a case report and literature review
por: Mori, Yusaku, et al.
Publicado: (2021)

Preliminary Observation of the Changes in the Intestinal Flora of Patients With Graves’ Disease Before and After Methimazole Treatment
por: Yang, Mengxue, et al.
Publicado: (2022)

Methimazole-induced insulin autoimmune syndrome in Graves' disease with hypokalemia: A case report and literature review
por: Han, Rongfeng, et al.
Publicado: (2020)

A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease
por: XU, Bin, et al.
Publicado: (2019)

Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves’ disease
por: Yasuda, Kie, et al.
Publicado: (2017)

Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU)
por: Kubota, Sumihisa
Publicado: (2016)

Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease
por: Kim, Hyun Joo, et al.
Publicado: (2017)

Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study
por: Lertwattanarak, Raweewan, et al.
Publicado: (2022)

Effects of methimazole on the elimination of irinotecan
por: van der Bol, Jessica M., et al.
Publicado: (2010)

The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
por: Wisnu, Wismandari, et al.
Publicado: (2021)

Case report: hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in young Taiwanese woman with Graves’ disease
por: Wu, Hsuan-Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmc3krl3qu3gkls9t8t6v2v396